SIG on PK/PD and Systems Pharmacology

Chair: Prof. Stephan Schmidt (USA)

Vice-Chairs: Prof. Hiroshi Suzuki (Japan) & Dr Masoud Jamei (United Kingdom)


The intensity and time-course of pharmacological effets (pharmacodynamics, PD) are the results of the complex interplay between drug- and system specific properties.

The time-course of drug concentrations (pharmacokinetics, PD) represents the driving force for the response to drugs, and major processes regulating drug exposure include absorption, distribution, metabolism and excretion (ADME / Systems pharmacology).

Clinical outcomes ultimately reflect PK/PD relationships that can be influenced by numerous pharmacological and (patho-)physiological factors.


The PK/PD and Systems Pharmacology SIG provides an international forum for the development and evaluation of methodologies that seek to translate PK/PD principlesfor the optimization of pharmaceutical care. Our goal is to bring together scientists engaged in Systems pharmacology and PK/PD research with clinical pharmacists to foster collaborations and facilitate the generation and dissemination of new approaches for advancing pharmacotherapy.

We also recognize education and training as a core component of this SIG and are working toward educational opportunities for our glbal members and recruitment strategies through state-of-the-art programming at the Annual FIP congress, as well as new electronic and online platforms.

For more information on this SIG, please contact Prof. Schmidt at

Annual Report 2017

The special interest group on PK/PD and Systems Pharmacology has had several successful activities in 2017. First, we combined efforts with the Systems Pharmacology SIG of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) and the American Conference on Pharmacometrics (ACoP) on “How to train the next generation of Pharmacometricians and Systems Pharmacologists”. To this end, we will co-host a symposium on March 20 prior to the Annual ASCPT meeting in Orlando, to which key opinion leaders in the quantitative clinical pharmacology arena will be invited in order to develop a respective white paper to be published in CPT:PSP. Second, we realized goals #1 and #3 for 2017 by forming a steering committee for the SIG as well as a joint symposium (with ISoP) on systems approaches to drug safety during PSWC 2017 in Stockholm, Sweden. Third, we initiated contact to the hospital pharmacy section within FIP for joint webinars in order to broaden awareness of pharmacometric and systems pharmacology approaches employed during drug development, regulatory decision making, and clinical practise. Third, we provided speaker support for a session on “One size doesn’t fit all: Dose individualisation with population pharmacology” during the 2017 FIP meeting in Seoul.

Goals for 2018:

Goal #1: Make better use of the steering committee for the SIG
Goal #2: Continue to set up joint webinars with the hospital pharmacy section with in FIP
Goal #3: Submit joint proposals with other professional organizations